Evidence map›Paper›PMID 42243653›Full record

ArticleBMC microbiology2026

Role of the gut microbiota-bile acid axis in liver fibrosis based on microbiomics and targeted metabolomics.

Yu-Lin Zhang, Hong-Zhong Gou, Zhen-Jiao Li, Jia-Hui Xi, Xiao-Juan Wang, Jin Shang, Dan Zhu, Long-Fei Ren, Xiao-Jun Shu, Lei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yu-Lin Zhang *The First Clinical Medical College, Lanzhou University, Lanzhou, China.
Hong-Zhong Gou *The First Clinical Medical College, Lanzhou University, Lanzhou, China.
Zhen-Jiao LiThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Jia-Hui XiThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Xiao-Juan WangThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Jin ShangThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Dan ZhuThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Long-Fei RenThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Xiao-Jun ShuThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Lei ZhangThe First Clinical Medical College, Lanzhou University, Lanzhou, China. ldyy_lzhang@lzu.edu.cn.

Funding

Fund of the First Hospital of Lanzhou University ldyyyn2023-87Gansu Provincial University Teachers' Innovation Fund Project 2025B-010Joint Scientific Research Foundation of Gansu Province 23JRRA1498Lanzhou Talent Innovation and Entrepreneurship Project 2019-RC-34National Natural Science Foundation of China 31960236Open Fund of Gansu Key Laboratory of Microorganisms for Extreme Environments EEMRE202403
6 · The paper itself

Abstract

backgroundEffective diagnoses and treatments for liver fibrosis (LF) are lacking. The gut microbiota (GM)-bile acid (BA) axis is critically associated with LF development and may represent a potential target for delaying or reversing LF.

methodsWe combined fecal microbiomics and BA-targeted metabolomics to characterize the GM-BA axis in rats with carbon tetrachloride (CCl₄)-induced LF and used fecal microbiota transplantation (FMT) and probiotics (Bifidobacterium quadruple viable tablet solution) to regulate the GM-BA axis to investigate the role of the GM-BA axis in LF and its related mechanisms.

resultsThe GM composition and GM β-diversity differed significantly between the control and model rats. Clostridia and others were significantly increased, whereas Bifidobacteriales and others were significantly decreased in model rats. Serum BA metabolism differed significantly between the groups. The concentrations of 19 BAs were significantly increased in model rats. FMT improved the disordered GM by increasing Bifidobacteriales and others and decreasing Clostridia and others. Probiotics improved the disordered GM by decreasing Clostridia, Lachnospiracea_incertae_sedis and others. FMT and probiotics improved BA metabolism by decreasing BAs such as tauroursodeoxycholic acid (TUDCA). FMT and probiotics were associated with a reduced degree of LF in model rats.

conclusionsThe GM-BA axis is strongly associated with LF, and the use of FMT and probiotics may contribute to regulating the GM-BA axis and to alleviating LF.

Indexed as

Bile Acids and SaltsGastrointestinal MicrobiomeLiver CirrhosisAnimalsCarbon TetrachlorideDisease Models, AnimalFecal Microbiota TransplantationFecesMaleMetabolomicsProbioticsRatsRats, Sprague-DawleyBile Acids and SaltsCarbon TetrachlorideBile acidsFecal microbiota transplantationGut microbiotaLiver fibrosisProbiotics

Identifiers

PMID42243653
PMCPMC13465787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.